8
Charlson Comorbidity Index showed that AD patients had an increased burden of comorbidities 1 6 0 compared to the matched population; this included a higher prevalence of autoimmune 1 6 1 comorbidities, including autoimmune thyroid diseases, type 1 diabetes mellitus, ulcerative 1 6 2 colitis, celiac disease and pernicious anemia (Table 1) .
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Baseline characteristics of the CAH cohort 1 6 4 In total, 602 patients fulfilled the CAH criteria and were subdivided into 254 glucocorticoid-1 6 5 treated patients (42.2%) and 348 patients not on glucocorticoids (57.8%). These were matched 1 6 6 with 508 and 696 unexposed controls, respectively (Table 2) .
The majority of CAH patients were female (72.3%), with a lower mean age in glucocorticoid-1 6 8 treated patients at cohort entry (33.4 vs. 36.9 years). CAH patients had a higher median BMI 1 6 9 compared to controls, and this was evident for both glucocorticoid-treated sub-cohort and the CAH sub-cohort never treated with glucocorticoids. CAH patients were more frequently 1 7 1 overweight or obese (60.3% vs. 44.2% in matched controls, p 0.001), and this was observed both in glucocorticoid-treated and untreated CAH patients (59.1 and 61.1%, respectively). The Glucocorticoid prescription 1 7 6 The most commonly prescribed type of glucocorticoid in the AD cohort was hydrocortisone (1296 patients, 82%), followed by prednisolone (187 patients, 11.8%). Only a minority of 1 7 8 patients were prescribed cortisone acetate (91 patients, 5.8%, no longer available in the UK) and dexamethasone (6 patients, 0.4%). In the glucocorticoid-treated CAH cohort, prednisolone was most commonly prescribed (127 1 8 1 patients, 50.0%), followed by hydrocortisone (96 patients, 37.8%), with a small minority 1 8 2 receiving dexamethasone (15 patients, 5.9%) or cortisone acetate (11 patients, 4.3%). Only five 1 8 3 CAH patients (2%) were prescribed a combination of short-and long-acting glucocorticoids. (Table 4 and Figure 1 ). However, when analyzing the population accordingly to 1 9 2 glucocorticoid use, only patients exposed to glucocorticoids had an increased risk of infections, and Figure 1 ). In this population-based study we found that the risk of three common infections (lower 2 0 7 respiratory tract, urinary tract, and gastrointestinal infections) was increased in the primary care 2 0 8 setting in patients with PAI, as compared to population-based matched controls. This was also 2 0 9 supported by our finding of increased prescription rates of antimicrobials in in patients with PAI.
Risk of Infections
Moreover, we found that CAH patients not receiving glucocorticoids did not have an increased Previous studies have described an increased infection-related mortality in patients with AD focused on hospital-treated infections only, possibly overestimating the actual incidence of this 2 2 0 complication due to a lower threshold for admission in PAI patients. In addition, information on 2 2 1 the actual etiology of PAI was not available in this study, as PAI was diagnosed on the basis of 2 2 2 concomitant glucocorticoid and mineralocorticoid prescriptions, which did not allow to 2 2 3 differentiate between AD, CAH, and other causes of PAI. Until recently, it was unclear whether the observed increase in infection episodes in patients
with PAI is related to the underlying disease itself or to the non-physiological delivery of frequently also suffer from other autoimmune comorbidities (16), and this was confirmed in our 2 2 8 study, with more prevalent autoimmune disease in AD patients than in matched controls. However, in CAH patients, there is only marginal evidence of an imbalance of immune function However, this was a secondary outcome, based on self-reported questionnaires on infections switch to modified-release hydrocortisone therapy (23). The findings of our study, including both 2 6 0 patients with AD and CAH, suggest that exogenous glucocorticoid is at least a contributory 2 6 1 factor to the increased infection risk we observed, given that no significant increase in infection 2 6 2 risk was observed in the CAH patients not receiving glucocorticoid therapy. Both our AD and CAH populations had increased prescription rates for antibiotics and 2 6 4 antifungals. Interestingly, increased prescription rates were also noted in the CAH patients not explained by a lower threshold for prescribing antimicrobials due to the perceived risk of adrenal 2 6 7 crisis in CAH patients; in fact, up to 60% of non-classic CAH patients, who usually do not The highest increase in risk of infection in our AD cohort was seen in GIIs, while for the CAH 2 7 1 cohort on glucocorticoids the most significant increase in risk was seen in LRTIs and UTIs; 2 7 2 however, the differences between the three infection groups was not statistically significant. This 1.4%, UTIs 8.5%). Therefore, the higher aIRR of LRTIs and UTIs in CAH patients is probably 2 7 8 related to a difference in age-related background risk. Our AD cohort had an age and sex distribution similar to the one reported in other papers (2,5), CaHASE study (28), with the possible exception of lower numbers of dexamethasone users in 2 8 5 our study. Taking this into account, our results can be assumed to be representative of the UK 2 8 6 AD and CAH populations.
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Our study has several strengths. We used a large population-based sample of patients of both 2 8 8 sexes, across all adult age groups, with very strict inclusion and exclusion criteria, allowing us to 2 8 9 include only patients with a true diagnosis of AD and CAH. Using the cohort study design, GPs and this could have resulted in some degree of misclassification of the exposed cohorts and of the different episodes of infection. Secondly, we could not evaluate the influence of used and due to the small number of infection events when further subdividing our populations 2 9 6 according to type of glucocorticoid. Thirdly, even though we tried to assess the impact of 2 9 7 associated comorbidities by adjusting for Charlson Comorbidity Index, this does not exclude the 2 9 8 possibility that some other confounders not accounted for in our analyses might have influenced 2 9 9 our results. Lastly, though there is some evidence of an immune-modulatory effect of androgens 3 0 0 (29), we could not take this into account in our population as we had no data on DHEA 3 0 1 replacement therapy in AD patients, since this is a hospital-prescribed drug in the UK; similarly,
we did not have data on biochemical control of androgen excess in the CAH patients. patients. This may also provide a case for recommending a vaccination strategy in PAI, e.g. 
